Loading...
Market
UniQure stock price increases by 20% or more by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news sites like Yahoo Finance or Bloomberg
Story
UniQure Sells Lexington Facility to Genezen for $25M, Outsources Hemgenix Manufacturing $QURE
Jul 1, 2024, 03:11 PM
UniQure has announced the sale of its commercial manufacturing facility in Lexington, Massachusetts, to Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector production. The deal, valued at $25 million, includes stock and debt. This move comes after UniQure laid off one-fifth of its staff and shuttered another research facility in Lexington in October. As part of the transaction, Genezen will acquire UniQure's commercial gene therapy manufacturing operations, which includes the production of Hemgenix. The sale allows UniQure to outsource the manufacturing of Hemgenix, a gene therapy product. The ticker symbols involved are $QURE and $PFE.
View original story
Similar markets
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Increase over 20% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
